D.E. Shaw & Co
OACC

D.E. Shaw & Co’s Oaktree Acquisition Corp III Life Sciences OACC Stock Holding History

D.E. Shaw & Co’s Portfolio OACC Stock Details OACC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.15M Hold
861,625
– – 0.01% 1718
2025
Q4 		$9.16M Hold
861,625
– – 0.01% 1840
2025
Q3 		$9.02M Hold
861,625
– – 0.01% 1765
2025
Q2 		$9.03M Hold
861,625
– – 0.01% 1574
2025
Q1 		$8.79M Buy
+861,625
New +$8.65M 0.01% 1494

Other funds holding OACC

AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $386M AUM 45.42% 1-Year Est. Return
FBCM
Fort Baker Capital Management Larkspur, California $1.27B AUM 25.46% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
BGIM
Boussard & Gavaudan Investment Management London, United Kingdom $1.06B AUM 4.58% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

D.E. Shaw & Co's OACC Position: Q1 2026 in Review

D.E. Shaw & Co held its Oaktree Acquisition Corp III Life Sciences (OACC) position steady in Q1 2026 at 861,625 shares worth $9.15M. The position accounts for 0.01% of the portfolio, ranked #1718.

D.E. Shaw & Co first reported a position in OACC in Q1 2025 and has held it in 5 quarters since. The position peaked at $9.16M in Q4 2025. 51 funds tracked by Wall St. Rank hold OACC as of Q1 2026.

  • D.E. Shaw & Co held 861,625 shares of Oaktree Acquisition Corp III Life Sciences worth $9.15M as of Q1 2026.
  • D.E. Shaw & Co left its Oaktree Acquisition Corp III Life Sciences share count unchanged in Q1 2026.
  • Oaktree Acquisition Corp III Life Sciences made up 0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1718 holding.
  • D.E. Shaw & Co first reported a position in Oaktree Acquisition Corp III Life Sciences in Q1 2025 and has held it in 5 quarters since.
  • D.E. Shaw & Co's Oaktree Acquisition Corp III Life Sciences position peaked at $9.16M in Q4 2025.
  • 51 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.